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berrant 
 
 
 
-catenin-TCF target gene activation
plays a key role in colorectal cancer, both in the
initiation stage and during invasion and metasta-
sis. We identiﬁed the neuronal cell adhesion molecule L1,
as a target gene of 
 
 
 
-catenin-TCF signaling in colorectal
cancer cells. L1 expression was high in sparse cultures
and coregulated with ADAM10, a metalloprotease in-
volved in cleaving and shedding L1’s extracellular domain.
A
 
L1 expression conferred increased cell motility, growth in
low serum, transformation and tumorigenesis, whereas its
suppression in colon cancer cells decreased motility. L1
was exclusively localized in the invasive front of human
colorectal tumors together with ADAM10. The transmem-
brane localization and shedding of L1 by metallopro-
teases could be useful for detection and as target for colon
cancer therapy.
 
Introduction
 
The development of human cancer is considered a multistage
process involving genetic changes endowing the tumor cells
first, with proliferative advantage and, at later stages, with the
capacity to breakdown cell–cell adhesions, and with motile
capacity, enabling the cancer cells to invade neighboring tissues.
In colorectal cancer, an early event is the aberrant activation
of 
 
 
 
-catenin-TCF signaling which results from mutations in
 
 
 
-catenin, or its degradation machinery, thereby leading to
the accumulation of 
 
 
 
-catenin in the nucleus where it forms
transcriptionally active complexes with LEF/TCF factors
(Bienz and Clevers 2000; Polakis, 2000; Conacci-Sorrell et al.,
2002a). Hyperactivation of growth promoting target genes of
 
 
 
-catenin-TCF signaling, including 
 
Cyclin D1
 
 (Shtutman et al.,
1999; Tetsu and McCormick, 1999) and 
 
c-myc
 
 (He et al., 1998)
may promote the onset of oncogenesis.
Inappropriate activation of 
 
 
 
-catenin signaling also
contributes to later stages of tumorigenesis by inducing genes
that confer invasive and metastatic capacities. These include
metalloproteases (Brabletz et al., 1999; Crawford et al., 1999;
Takahashi et al., 2002; Hlubek et al., 2004), ECM components
(Gradl et al., 1999; Hlubek et al., 2001) and cell adhesion
receptors such as CD44 (Wielenga et al., 1999), Nr-CAM
(Conacci-Sorrell et al., 2002b), and uPAR (Mann et al., 1999).
In addition to its role as cotranscriptional activator, 
 
 
 
-catenin
is a major component of adherens junctions linking cad-
herin family transmembrane receptors to the actin cytoskeleton
(Ben-Ze’ev and Geiger, 1998). By playing a dual role in cell
adhesion and transcriptional regulation, 
 
 
 
-catenin can integrate
changes in these two key cellular processes that are disrupted
in cancer cells.
Recent studies of human colorectal cancer tissue support
this view by demonstrating reversible changes in E-cadherin
and 
 
 
 
-catenin localization during metastasis. Cells at the central
tumor mass in the primary tumor display polarized epithelial
organization, and form tubular structures with junctional local-
ization of 
 
 
 
-catenin and E-cadherin, whereas cells at the invasive
front are characterized by loss of cell-surface E-cadherin and
nuclear localization of 
 
 
 
-catenin (Brabletz et al., 2001). Inter-
estingly, in lymph node metastases, these two phenotypes of
cellular organization seen in the primary tumor are regained,
suggesting  plasticity in colon cancer cellular morphogenesis
during metastasis (Barker and Clevers, 2001; Brabletz et al.,
2001). Using a model system of colon cancer cells grown at
varying densities in vitro, we could mimic these two different
forms of cellular organization and identified signaling path-
ways linking the negative regulation of E-cadherin expression
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with nuclear signaling by 
 
 
 
-catenin (Conacci-Sorrell et al.,
2003). Sparse cultures of colon cancer cells express only small
amounts of E-cadherin and high levels of nuclear 
 
 
 
-catenin,
reminiscent of colon cancer cells at the invasive tumor front,
whereas dense cultures have well-developed E-cadherin and
 
 
 
-catenin–containing adherens junctions with little nuclear
 
 
 
-catenin resembling the central, more differentiated part of
colorectal tumors (Brabletz et al., 2001; Conacci-Sorrell et al.,
2003).
In the present study, we used this cell culture system to
characterize a novel target gene of 
 
 
 
-catenin signaling in-
volved in human colon cancer invasion, and determined the
localization of its gene product in colon cancer tissue. We
identified L1, a transmembrane cell adhesion molecule, nor-
mally expressed in nerve cells, as a target of 
 
 
 
-catenin-TCF
signaling, and showed that its expression confers cell motil-
ity, invasion and tumorigenesis in fibroblasts and colon can-
cer cells. In colorectal cancer tissue, L1 was exclusively lo-
calized at the invasive front of the tumor tissue that expresses
nuclear 
 
 
 
-catenin, together with the metalloprotease ADAM10
that is involved in the cleavage and shedding of the L1 extra-
cellular domain.
 
Results
 
Cell density–dependent expression of L1 
and ADAM10 in colon cancer cells
 
We used the density-dependent phenotypic conversion dis-
played by two human colon cancer cells lines, SW480 and
HCT116, that mimic the changes in E-cadherin and 
 
 
 
-catenin
localization, and in E-cadherin expression, displayed by colon
cancer cells in the differentiated part and the invasive front of
colorectal tumors (Brabletz et al., 2001; Conacci-Sorrell et al.,
2003). SW480 cells have mutant APC, and wt 
 
 
 
-catenin accu-
mulates in the nuclei of these cells in sparse cell cultures (Fig. 1
C). In HCT116 cells, a stabilizing mutation in the NH
 
2
 
 termi-
nus of 
 
 
 
-catenin (on Ser45) is responsible for its accumulation
and increased nuclear signaling (Morin et al., 1997). When
looking for novel 
 
 
 
-catenin target genes that correlate with the
invasive phenotype of human colon cancer cells, we reasoned
that L1 might be a good candidate, as it is among genes whose
expression decreased in a DNA microarray analysis of SW480
cells transduced with wt APC (Lin et al., 2001). In addition, we
recently identified another member of the L1 family, Nr-CAM,
as a target gene of 
 
 
 
-catenin, and showed that its expression is
induced in human melanoma and colon carcinoma (Conacci-
Sorrell et al., 2002b).
We compared the expression of L1 in sparse and dense
cell cultures of both SW480 and HCT116 cells and found that
sparse cells express higher levels of L1 than dense cells (Fig.
1 A), whereas E-cadherin expression behaved in the opposite
manner. The higher level of L1 in sparse cultures resulted
from increased L1 RNA in these cells (Fig. 1 B). Sparse
SW480 cells displayed strong cytoplasmic L1 distribution,
often in large vesicles (Fig. 1 C, arrows), whereas in dense
cultures, a weaker staining of L1 was found in the membrane
at cell–cell contact sites, consistent with the capacity of L1 to
mediate homophilic cell–cell interactions. However, this lo-
calization of L1 in dense cells did not coincide significantly
with adherens junctions visualized by staining for 
 
 
 
-catenin
(Fig. 1 C, dense, merge). The presence of L1 in vesicles and
its reported shedding from the surface of some tumor cells
mediated by the metalloprotease ADAM10 (Mechtersheimer
et al., 2001), prompted us to examine whether L1 can be
found in the culture medium of sparse and dense colon cancer
cells. When the medium was analyzed from cells expressing
equivalent amounts of cell-associated L1 (Fig. 1 D, lanes 3
and 4), we found much more L1 shedded into the medium of
sparse than dense cell cultures (Fig. 1 D, lanes 1 and 2).
Moreover, in both SW480 and HCT116 cells more ADAM10
was found in sparse cell cultures (Fig. 1 E), and correlated
with the higher levels of ADAM10 RNA in such cells (Fig. 1
F). These results indicate that L1 might be a novel target gene
of 
 
 
 
-catenin signaling, coexpressed with ADAM10 in sparse
Figure 1. Coregulation of L1 and ADAM10 expression by cell density in
human colon cancer cells. (A) Expression of L1 in sparse and dense cultures
of HCT116 and SW480 cells was compared with E-cadherin. Tubulin
served as loading control. (B) RNA levels were determined by RT-PCR. (C)
The localization of L1 and  -catenin in sparse and dense cultures was
compared by double immunostaining for L1 and  -catenin (arrows point to
L1 in vesicles). (D) The levels of L1 in culture medium of sparse and dense
cultures were compared by loading equivalent volumes of medium corre-
sponding to cells expressing equal amounts of cell-associated L1 (lanes 3
and 4). More medium and cell lysates from dense cultures were required
to obtain an equal amount of cell-associated L1 (see the level of  -catenin).
(E) L1 and ADAM10 levels were compared in sparse and dense cultures
of SW480 and HCT116 cells. (F) ADAM10 RNA levels in sparse and
dense cultured of SW480 cells were determined by RT-PCR with GAPDH
RNA serving as loading control. 
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cell cultures that mimic the invasive phenotype of human co-
lon carcinoma.
 
The 
 
L1
 
 promoter is activated by 
 
 
 
-catenin-TCF signaling
 
We wished to determine whether the 
 
L1
 
 gene is a target for
activation by 
 
 
 
-catenin-TCF signaling. When an 
 
L1
 
 pro-
moter reporter plasmid containing 2.9-kb upstream of the
transcription initiation site (Fig. 2 C; Kallunki et al., 1997;
Meech et al., 1999) was cotransfected with a point mutant
(S33Y) stabilized 
 
 
 
-catenin into 293 cells, it was activated
sixfold (Fig. 2 A), similar to the 
 
Cyclin D1
 
 promoter reporter
that served as control for a previously characterized 
 
 
 
-cate-
nin target gene (Shtutman et al., 1999). Cotransfection of the
cytoplasmic tail of cadherin, that binds to and sequesters
 
 
 
-catenin from binding to LEF/TCF factors (Sadot et al., 1998),
inhibited 
 
L1
 
 transactivation. The involvement of LEF/TCF
factors in L1 transactivation is suggested by the inhibition of
 
L1
 
 promoter activation using a dominant negative LEF-1
(
 
 
 
NLEF), whereas a dominant positive LEF-1 construct
containing the DNA-binding domain of LEF-1 linked to the
transactivation domain of viral VP16, activated the 
 
L1
 
 pro-
moter (Fig. 2 A, LEF1/VP16). Transactivation of the 
 
L1
 
 pro-
moter by endogenous 
 
 
 
-catenin-TCF complexes in SW480
and HCT116 colon cancer cells was inhibited by cotransfec-
tion of components involved in 
 
 
 
-catenin degradation (APC
and Axin), and also by the cytoplasmic cadherin tail (Fig. 2
B). Both, the 
 
Cyclin D1
 
 promoter and the synthetic TOP-
FLASH reporter plasmid, containing several LEF/TCF-bind-
ing sites, displayed similar responses in these experiments
(Fig. 2 A and B). We identified 4 putative TCF-binding sites
in the 2.9-kb of the 
 
L1
 
 promoter (Fig. 2 C). In DNA electro-
phoretic mobility shift analyses, all 4 putative TCF-binding
sites bound to protein complexes containing 
 
 
 
-catenin-TCF
derived from nuclear extracts of SW480 cells (the data for ra-
diolabeled site no. 4 are shown in Fig. 2 D). When radiola-
beled site no. 4 was incubated with nuclear extracts from
SW480 cells and with antibody to 
 
 
 
-catenin, a supershift
band was detected (Fig. 2 D, lane 8), indicating the presence
of 
 
 
 
-catenin in this DNA–protein complex. This binding was
inhibited by incubation with increasing concentrations of the
TCF-binding site of the 
 
Cyclin D1
 
 promoter (Fig. 2 D, com-
pare lanes 3–5 with lane 2).
Next, we examined whether endogenous 
 
 
 
-catenin-TCF
signaling activates the endogenous 
 
L1
 
 gene of colon cancer
cells, using HCT116 cells expressing doxycycline inducible
siRNA to 
 
 
 
-catenin and dominant negative TCF4 (
 
 
 
NTCF;
van de Wetering et al., 2003). The efficiency of this strategy in
suppressing 
 
 
 
-catenin-TCF signaling was demonstrated by re-
duced TOPFLASH activity 2 d after doxycyclin-mediated in-
duction of 
 
 
 
NTCF or 
 
 
 
-catenin siRNA (Fig. 2 E). The siRNA
to 
 
 
 
-catenin also reduced the level of 
 
 
 
-catenin (Fig. 2 F, com-
pare lanes 7 and 8 with lanes 5 and 6). Analysis of L1 expres-
sion in such HCT116 cells, where 
 
 
 
-catenin levels were sup-
pressed, revealed a major decrease in L1 (Fig. 2 F, lanes 7 and 8).
Similarly, when TCF-mediated signaling was inhibited by in-
ducible 
 
 
 
NTCF4, L1 expression was also diminished (Fig. 2 F,
compare lanes 3 and 4 with lanes 1 and 2). Together, these data
argue that 
 
 
 
-catenin-TCF signaling can induce the 
 
L1
 
 gene of
human colon cancer cells.
 
Expression of L1 in fibroblasts confers 
enhanced motility, growth in low serum, 
transformation, and tumorigenicity in 
nude mice
 
To understand the possible role(s) of L1 in development of
the tumorigenic phenotype, we considered the known func-
tions of L1 in nerve cells, where it is involved in neuronal
migration, axonal growth, and guidance (Kamiguchi et al.,
Figure 2. The L1 gene promoter is activated by  -catenin-TCF signaling
in colon cancer cells. (A) The L1, Cyclin D1, and TOPFLASH promoter
reporter plasmids were transfected into 293 cells together with  -galac-
tosidase that served to normalize for transfection efficiency. Cells were
cotransfected with either a stabilized, activated  -catenin S33Y mutant
( -cat), with mutant  -catenin and the cytoplasmic tail of cadherin (Cad tail),
or with  NLEF lacking the DNA-binding domain ( NLEF). Cells were also
cotransfected with these gene reporters and a dominant positive LEF1/
VP16 construct. Fold activation for TOPFLASH was determined after dividing
promoter activity by the values obtained with the mutant FOPFLASH
construct. For the other gene promoters, the values were divided by those
obtained with empty vector. (B) Activation of L1 and the other gene
promoters described in A by endogenous  -catenin-TCF complexes in
SW480 and HCT116 colon cancer cells. Cells were transfected with the
promoter reporter plasmids in the presence or absence of cDNAs encoding
for components that enhance  -catenin degradation (APC, Axin),  NLEF,
and the cytoplasmic tail of cadherin (Cad tail) that sequesters  -catenin
from binding to TCF. (C) Schematic representation of putative TCF-binding
sites in the L1 promoter. (D) DNA mobility shift assays with nuclear ex-
tracts from SW480 cells incubated with 
32P-radiolabeled TCF-binding site
no. 4 of the L1 promoter and increasing concentrations of competing non-
radioactive Cyclin D1 promoter TCF-binding sequences (CD1) (lanes 3–5),
or increasing concentrations of anti– -catenin antibody (lanes 6–8). (E)
Activity of transfected TOPFLASH in HCT116 cells after doxycycline (Dox)-
mediated induction of  NTCF4 and  -catenin siRNA. Values were deter-
mined 2 and 3 d after induction. (F) Levels of L1 and  -catenin in HCT116
cells expressing inducible  NTCF4 and  -catenin siRNA. Error bars repre-
sent one SD.JCB • VOLUME 168 • NUMBER 4 • 2005 636
1998). To examine if L1 expression can affect the motility of
other cells, we infected NIH3T3 cells with a retrovirus ex-
pressing L1, and selected cells resistant to a cotransfected
puromycin-resistance gene (Fig. 3 B, puro). As shown in Fig.
3 A, NIH3T3 cells transduced with L1 displayed L1 in the cy-
toplasm (when grown at low density), mostly in vesicles, and
in long cellular processes (Fig. 3 A, arrows). This organiza-
tion was reminiscent of the vesicles seen in SW480 cells (Fig.
1 C). At higher cell density, L1 localized at cell–cell contacts
(Fig. 3 A, dense), as seen in dense cultures of colon cancer
cells (Fig. 1 C). Most significantly, L1 expressing NIH3T3
cells formed foci when grown on plastic, whereas puro
r cells
did not (Fig. 3 C). We examined whether L1 expression influ-
ences the motility of NIH3T3 cells by introducing a gap in a
confluent monolayer of cells, and followed the rate at which
control and L1 expressing cells filled the gap. L1 expressing
3T3 cells moved into the denuded area much faster than puro
r
control cells (Fig. 3 D). Because NIH3T3 cells expressing L1
formed foci (Fig. 3 C), indicating that L1 can confer cell
transformation, we examined if these cells are tumorigenic in
nude mice. We found that all six mice injected with L1 ex-
pressing cells formed tumors, whereas only one mouse devel-
oped a small tumor when injected with the puro
r control cells
(Fig. 3 E, arrow). When higher numbers of cells were injected
into mice, puro
r-expressing cells also formed tumors (Fig. 3 F),
a property inherent to transduction with retroviral constructs.
However, tumors formed by puro
r cells were at least three
times smaller than those formed by L1-expressing cells (Fig.
3 F). Analysis of RNA from tumor tissue revealed that L1 is
expressed in the tumors obtained with NIH3T3 cells express-
ing L1 (Fig. 3 G).
We examined the growth properties of NIH3T3 cells ex-
pressing L1 and found that in 10% of serum there were no dif-
ferences between the growth rates of these cells and either
control NIH3T3 cells, or puro
r cells (Fig. 4 A). In 0.5% of se-
rum however, L1 expressing cells continued to grow and
formed foci (Fig. 4 C), whereas control NIH3T3 and puro
r
cells died after a few days (Fig. 4 B). We wished to determine
which signaling pathways enabled L1 expressing NIH3T3
cells to grow in low serum. Cells were incubated in 0.5% of
serum for 24 h and the levels of total ERK and activated (phos-
phorylated) ERK were determined. L1 expressing cells dis-
played constitutively activated ERK, whereas puro
r cells had
no detectable P-ERK (Fig. 4 D, compare lane 1 with lane 2).
When these cells were grown in 0.5% of serum and incubated
with 10% of serum to induce ERK activation, both puro
r and
L1 expressing cells maintained the ability to induce P-ERK
upon serum stimulation (Fig. 4 D, lanes 3–8). This transient
induction of ERK activation declined to undetectable levels by
24 h in puro
r cells, whereas L1 expressing cells continued to
display sustained levels of P-ERK (Fig. 4 D, lanes 9 and 10).
These results on ERK activation by L1 are in agreement with
recent studies by Silletti et al. (2004).
In a previous study, expression of L1 was detected among
genes suggested to be required for the growth of a variety of
tumor, but not normal cells (Primiano et al., 2003). Hence, we
examined if L1 is necessary for SW480 and HCT116 cell
proliferation by incubating these cells with an antibody recog-
nizing the extracellular domain of L1. As control, cells were
incubated with denatured antibody (by boiling to destroy its
activity). The L1 antibody blocked very effectively the prolif-
eration of both SW480 and HCT116 cells (Fig. 4, E and F),
suggesting that L1 expression is essential for colorectal can-
cer cell growth.
Overexpression of L1, or its 
suppression, affect cell motility, 
invasion, and tumorigenesis of colon 
cancer cells
To examine if L1 plays a role in determining the motile, inva-
sive, and tumorigenic capacity of human colon cancer cells,
we expressed L1 in LS174T human colon cancer cells that do
not normally express L1 (Fig. 5 A), and found that L1 is
mainly localized at cell–cell contact sites of such dense
cell cultures (Fig. 5 B). Two independently isolated LS174T
clones expressing L1 displayed an increased capacity to close
an artificial wound introduced in a monolayer compared with
control, neo
r cells (Fig. 5 C). When LS174T-neo
r cells were
injected into one side of six nude mice, the L1 expressing cells
Figure 3. Expression of L1 in NIH3T3 cells confers enhanced motility,
transformation and tumorigenesis in nude mice. (A) NIH3T3 cells were
infected with a retrovirus construct coding for L1 and the puro
r gene, or
puro
r alone, and puro
r cells were selected. The organization of L1 in these
cells was determined by staining with antibody to L1 in sparse and dense
cell cultures. (B) Expression of L1 in NIH3T3 cells was compared (by West-
ern blotting) to that of 293T cells transiently transfected with L1 cDNA. (C)
The growth of L1 expressing cells that formed foci is compared with puro
r
controls at low and high magnification under a microscope. (D) The motile
capacity of L1 expressing NIH3T3 cells expressing puro
r alone, or to-
gether with L1, was compared in closing an artificial wound introduced
into a confluent monolayer. The picture was taken 16 h after “wounding”
the monolayer. (E) The ability of NIH3T3-puro
r cells and cells expressing L1
(NIH3T3-L1) to form tumors was determined by injecting (subcutaneously)
groups of six mice with 10
5 and 2.5   10
5 cells, and (F) by measuring
tumor weight after 2 wk. Error bars represent one SD. (G) Expression of L1
RNA in the tumor tissue and dermis was determined by RT-PCR.THE ROLE OF L1 IN HUMAN COLON CANCER INVASION • GAVERT ET AL. 637
injected on the other side formed much larger tumors (Fig. 5
D). This was observed with two distinct LS174-L1 cell clones
(Fig. 5 E). Using another colon cancer cell line, SW707, that
also lacks L1 (Fig. 5 F), we compared the haptotactic motility
(toward fibronectin) in transwell filter assays before, and after
their stable transfection with L1. We found that such cells dis-
play enhanced haptotactic motility compared with empty vec-
tor transfected cells (Fig. 5 G). Moreover, L1-transfected
SW707 cells were more invasive through filters coated with
matrigel than control SW707 cells (Fig. 5 H), and when in-
jected into mice formed larger tumors (Fig. 5 I), indicating
that L1 can confer enhanced ECM invasion and tumor growth
also in these colon cancer cells. In contrast, suppression of en-
dogenous L1 levels in HCT116 cells by L1 siRNA oligonucle-
otides (Fig. 5 J) led to decreased haptotactic motility (Fig. 5
K), whereas further elevation of L1 in HCT116 cells, by ade-
novirus-mediated infection, increased their motility (not de-
picted). Together, these results imply that L1 expression in
human colon cancer cells plays an important role in their mo-
tile, invasive and tumorigenic capacities.
Expression of L1 and ADAM10 at the 
invasive front of human colorectal tumor 
tissue
We wished to detect and localize the expression of L1 in hu-
man colorectal cancer tissue. For this, we performed histo-
chemical staining with antibodies to L1 and  -catenin in serial
Figure 4. L1 can regulate cell proliferation, survival and MAPK activation.
The proliferation of control NIH3T3 cells, puro
r expressing cells and cells
expressing L1 was compared in the presence of 10% (A) and 0.5% (B)
serum. (C) NIH3T3 cells expressing L1 formed foci when grown in 0.5% of
serum on plastic, but puro
r cells did not. (D) NIH3T3 cells expressing L1
maintained a constitutive level of activated ERK (P-ERK) (lanes 1 and 9),
whereas puro
r cells did not (lanes 2 and 10). Activation of ERK by serum
stimulation, in cells grown for 2 d in 0.5% of serum, was similar in puro
r
and L1 expressing cells (lanes 3–8). An antibody to the extracellular
domain of L1 inhibited HCT116 (E) and SW480 (F) cell growth. Denatured
L1 antibody (by boiling) served as control. Error bars represent one SD.
Figure 5. L1 expression in colon cancer cells enhances their migration,
ECM invasion and tumorigenesis, whereas its suppression inhibits cell motility.
(A) LS174T colon cancer cells lacking L1 were stably transfected with neo
r
alone (LS174T-neo
r), or together with L1 and individual L1-expressing
clones (LS174T-L1/1; LS174T-L1/2) and neo
r clones were identified by
Western blotting and compared with endogenous L1 levels expressed by
SW480 cells. (B) Transfected L1 was localized at cell–cell contacts in
LS174-L1 cells. Bar, 10  m. (C) The ability of LS174-L1 cell clones to close
an artificial wound was enhanced and (D and E) these cells formed larger
tumors when injected into nude mice compared with neo
r cells. (F)
SW707 colon cancer cells lacking L1, when stably transfected with L1 dis-
played enhanced haptotactic motility toward fibronectin (transwell analysis;
G), increased invasion through matrigel (H), and increased capacity to
form tumors in nude mice (I). HCT116 colon cancer cells in which endoge-
nous L1 levels were suppressed by siRNA (J) had reduced haptotactic
motility compared with control (K). Error bars represent one SD.JCB • VOLUME 168 • NUMBER 4 • 2005 638
paraffin sections of both normal and tumor tissue derived
from surgical resections. In normal colon epithelium, we ob-
served  -catenin staining at cell–cell contact sites (Fig. 6 B),
and only sporadic staining for L1 along intramucosal nerve
axons (Fig. 6 A, arrow). In the central, differentiated area of
the tumor,  -catenin overexpression was detected in both the
membrane and cytoplasm (Fig. 6 D), and often in the nuclei of
cells (Fig. 6 D, arrowhead; unpublished data). Yet, we did not
detect L1 in this part of the tumor tissue (Fig. 6 C) after analyz-
ing 25 colorectal adenocarcinomas. In contrast, the invasive
front of tumors displayed strong L1 expression in budding tu-
mor cells at the interphase between tumor and normal tissue
(Fig. 6, E and G, arrowheads) and in nerve axons (Fig. 6 E, ar-
row). This phenotype was apparent in 68% of the tumors.
Higher magnification of the invasive tumor front displayed
strong L1 expression in invading tumor cells and also in dis-
seminated, single tumor cells (Fig. 6 G) expressing nuclear
 -catenin (Fig. 6 H, arrowhead). Interestingly, in some sections
where the nerve axons were more readily detectable, we ob-
served L1 expressing cancer cells (Fig. 6 I, arrowhead) display-
ing nuclear  -catenin (Fig. 6 J, arrowhead) at the invasive front
of the tumor, growing directly along L1 expressing nerve axons
(Fig. 6 I, arrow). Because both these cancer and nerve cells ex-
press L1 on their surface, L1-mediated adhesive interactions
among such cells might guide the further dissemination of in-
vading tumor cells.
Because we found that L1 and ADAM10 expression in
colon cancer cells is coregulated by changes in cell culture den-
sity (Fig. 1, D–F), and ADAM10 is involved in the cleavage
and shedding of the extracellular domain of L1 (Gutwein et al.,
2003), we determined the expression of ADAM10 in human
colorectal cancer tissue. Staining with antibody to ADAM10
(and in adjacent sections for L1) of colon cancer tissue re-
vealed that in 74% of tumors (19 tumors were analyzed), L1
and ADAM10 colocalized at the invasive front of the tumor tis-
Figure 6. L1 is expressed in tumor cells at the invasive front of colorectal
carcinomas often in contact with nerve axons. Immunohistochemical staining
(brown) of L1 and  -catenin in adjacent serial sections with nuclear counter-
staining (blue). (A and B) No L1 expression was seen in normal epithelial
cells of the mucosa displaying membranal  -catenin. Weak staining for L1
was evident in intramucosal nerve axons (A, arrow). (C and D) No L1
expression was observed in the central, differentiated areas of the tumor.
The arrowhead in D points to two cells displaying nuclear  -catenin. (E
and F) Overview (at low magnification) of the invasive tumor front show-
ing L1 in budding tumor cells, at the invasive front (arrowheads), and in
nerve axons (arrows). (G and H) Higher magnification of E and F showing
strong L1 expression in invading tumor cells and disseminated, single
tumor cells expressing nuclear  -catenin (arrowheads). (I and J) Nuclear
 -catenin positive tumor cells expressing L1 at the invasive front (arrowheads)
grow in contact with L1 expressing nerve axons (arrows). Bar: (E and F)
375  m; (A–D and G–J) 75  m.
Figure 7. Coexpression of L1 and ADAM10 in tumor cells at the invasive
front of colorectal carcinomas. Immunohistochemical stainings of L1
(brown) and ADAM10 (red) in adjacent serial sections, with nuclear coun-
terstaining in blue. Bar: (A and B) 75  m; (C and D) 37.5  m.THE ROLE OF L1 IN HUMAN COLON CANCER INVASION • GAVERT ET AL. 639
sue (Fig. 7, A–D). These results indicate that L1 might be an
important target gene of  -catenin-TCF signaling playing a key
role, together with ADAM10, in the invasion of human colo-
rectal cancer cells.
Discussion
L1 is a novel target of  -catenin-TCF 
signaling in colon cancer cells
In the present study, we demonstrated that in colon cancer cells
the   -catenin-TCF transcriptional complex activates the L1
gene, coding for a cell adhesion molecule mostly expressed in
nerve cells. L1 levels were high in sparse cultures of colon can-
cer cells displaying characteristics of colorectal cancer cells at
the invasive front of tumors (Brabletz et al., 2001). These
include nuclear localization and signaling by  -catenin and
down-regulation of E-cadherin by Slug, a negative transcrip-
tional regulator of E-cadherin induced by  -catenin-TCF sig-
naling (Conacci-Sorrell et al., 2003). Inhibition of  -catenin-
TCF signaling in cultured colon cancer cells by inducible
 NTCF, or suppression of  -catenin levels by inducible
 -catenin siRNA, both reduced the expression of endogenous
L1 in these cells (Fig. 2 F). In addition, the  -catenin-TCF
complex in 293 cells and colorectal cancer cell lines activated
the L1 promoter reporter. Together, these results support the
view that L1 is a novel target gene of  -catenin signaling. This
conclusion is in agreement with a previous study using DNA
microarrays to determine genes down-regulated when wt APC
was reintroduced into SW480 cells, and detected L1 among
such genes (Lin et al., 2001).
The biological activities of L1 in tumor 
cells
During tumor cell invasion, cancer cells often activate genes
that normally promote the growth and migration of normal
cells (in the course of various biological processes), to promote
tumor cell metastasis. L1 is known for its important function in
nerve cell axonal guidance, outgrowth, and pathfinding (Ka-
miguchi et al., 1998; Kenwrick et al., 2000), and its disruption
causes serious damage to the nervous system, including mental
retardation (De Angelis et al., 2002) and intestinal agangliono-
sis (Parisi et al., 2002). In addition, L1 was also found in other
specialized sites including a subclass of lymphocytes, intestinal
crypt cells, and kidney tubule epithelia (Kowitz et al., 1993;
Thor et al., 1987; Debiec et al., 1998). We have shown that ex-
pression of L1 in NIH3T3 cells (that lack L1) confers several
properties characteristic of cancer cells, including enhanced
motility, cell transformation (manifested by the formation of
foci in cells grown on plastic), and the ability to grow in low
serum. Because NIH3T3 cells are preneoplastic, it remains to
be determined whether L1 can transform normal, primary epi-
thelial cells. The ability of L1 to confer NIH3T3 growth in the
absence of serum is related to constitutively activated ERK dis-
played by these cells (Fig. 4 D). Activation of the MAPK path-
way by L1 was reported previously (Schaefer et al., 1999), and
recently linked to the enhanced motility of 3T3 fibroblasts and
melanoma cells (Silletti et al., 2004). Because constitutive
ERK activation is considered a key step in cell transformation
and the development of various tumors (Cowley et al., 1994;
Hoshino et al., 1999; Welsh et al., 2000), its activation by L1
supports the notion that ERK-mediated gene expression is the
major survival pathway allowing the proliferation of these cells
in low serum. L1 expression also endowed these cells with in-
creased tumorigenic capacity in nude mice, a finding similar to
that reported with Nr-CAM, another L1 family member that is
also a target gene of  -catenin-TCF signaling, overexpressed in
melanoma and colon carcinoma tissue (Conacci-Sorrell et al.,
2002b). The role of L1 in human colon cancer cell invasion and
tumorigenesis is further supported by our data showing that its
expression in human colon cancer cells lacking L1 increases
haptotactic and invasive motility, and leads to faster tumor
growth, whereas siRNA-mediated suppression of endogenous
L1 in human colon cancer cells decreases cell motility (Fig. 5).
Hence, L1 family members could function as potential promot-
ers of colon cancer cell growth and invasion by being target
genes of hyperactive  -catenin signaling.
Involvement of L1 and ADAM10 in 
human cancer invasion
Using the cell culture density model of human colon cancer
cells, we found that the expression of L1 and of ADAM10 that
mediates L1 cleavage and shedding (Mechtersheimer et al.,
2001; Gutwein et al., 2003), is coregulated. Sparse cell cultures
had much higher levels of L1 and ADAM10 protein and RNA
than dense cultures (Fig. 1). Therefore, we analyzed their ex-
pression in human colorectal cancer tissue and compared it to
that of  -catenin. We observed a very unique localization of L1
in a subpopulation of cancer cells expressing nuclear  -catenin
at the invasive tumor front (in  70% of the tumors), but not in
the central, more differentiated part of the tumor (Fig. 6, C–H).
This finding strongly supports a role for L1 in the invasive pro-
cess of human colorectal cancer cells in vivo. ADAM10 ex-
pression was similarly enriched in the invasive front of such tu-
mors (Fig. 7), indicating that L1 shedding into the surrounding
microenvironment may play a role in dissemination of colon
carcinoma cells. Interestingly, we often observed in very close
proximity to the invasive front of tumors nerve axons, the only
other cell type expressing L1 in colon mucosa (Fig. 6, E and J).
The close apposition of invading tumor cells expressing L1, ei-
ther on their surface (or as shedded molecules in their micro-
environment), to L1 expressing nerve axons, could promote
adhesive interactions between tumor and nerve cells, thereby
contributing to colon cancer cell invasion using axons as tracks
for migration. Studies using cocultures of neuronal and colon
cancer cells should shed light on the possible mechanisms in-
volving such interactions and the cross signaling between the
different cell types.
 -Catenin-TCF activation of target genes is also known
to regulate normal epithelial colon cell proliferation along the
crypt-villus interface (van de Wetering et al., 2002). The Wnt/
 -catenin target genes involved, include the ephrins and their
receptors (Batlle et al., 2002). These molecules help establish-
ing the boundary between proliferating and differentiated cells
in the highly dynamic and renewing colon epithelium (Peifer,JCB • VOLUME 168 • NUMBER 4 • 2005 640
2002). These same ephrins and their receptors are known to set
segmental boundaries in the brain and determine axonal guid-
ance in the retina. This points to another set of “brain-specific”
cell adhesion molecules as key regulators of both normal and
perhaps pathological behavior in the human colon.
L1 was previously detected in some normal tissues in-
cluding leukocytes, intestinal crypt cells and kidney tubule epi-
thelia (for review see Kenwrick et al., 2000), and the involve-
ment of L1 in the motile and invasive properties of a variety of
cultured cancer cell lines (lymphoma, lung carcinoma, mela-
noma) was also suggested (Kowitz et al., 1993; Miyahara et al.,
2001; Thies et al., 2002). The shedding of the L1 ectodomain
by ADAM10 and its activity in promoting cell adhesion by
mechanisms involving integrin receptors was demonstrated in
several cancer cell lines (Mechtersheimer et al., 2001). A re-
cent study using transcriptome-scale selection to identify sup-
pressors of breast carcinoma cell growth discovered L1 as a
major positive regulator of carcinoma (but not normal) breast
epithelial cell growth, and also of some colon and cervical can-
cer cell lines (Primiano et al., 2003). In agreement with these
findings, we found that the proliferation of both SW480 and
HCT116 cells is inhibited when they are incubated with anti-
L1 antibody (Fig. 4), suggesting a key role for L1 in tumor cell
growth. L1 and ADAM10 expression were also recently de-
tected in ovarian and uterine carcinomas, and L1 shedding into
the serum and ascites of such patients was suggested to be a
predictive marker for their clinical outcome of (Fogel et al.,
2003). Because endometrial carcinoma is often associated with
aberrant activation of the  -catenin signaling pathway (Pala-
cios and Gamallo, 1998; Moreno-Bueno et al., 2002), it could
be that in endometrial tumors, as well, activation of L1 is medi-
ated by hyperactive  -catenin signaling. Together with the
present study, these results imply that induction of L1 expres-
sion by  -catenin in malignant tumors might represent another
case of opportunistic activation of target genes normally ex-
pressed in other tissues in the course of various biological
processes. This property of cancer cells may facilitate their
invasion and metastasis.
Materials and methods
Cell lines and cell culture
293, NIH3T3, SW480, LS174T, SW707, and HCT116 cells were main-
tained in DME with 10% bovine calf serum (BCS). NIH3T3 cells expressing
puro
r constructs were cultured in 10  g/ml puromycin. HCT116 clones ex-
pressing the Tet-repressor were obtained from M. van de Wetering and H.
Clevers (Hubrecht Laboratory, Utrecht, Netherlands), and were grown in
RPMI with 5% FCS and Zeocin (500  g/ml). HCT116 cells expressing in-
ducible,  NTCF4, or siRNA to  -catenin, were prepared as described pre-
viously (van de Wetering et al., 2003), and obtained from M. van de We-
tering. They were cultured with Zeocin (500  g/ml) and Blasticidin (10
 g/ml). Transgenes were induced with 1  g/ml doxycycline. Activation of
MAPK was tested in cells starved for 18 h in DME. The cells were collected
before, and at different times after incubation with 10% BCS.
Transfections and retroviral infection
Transient transfection of 293T cells was performed using calcium phos-
phate. SW480 and HCT116 cells were transfected using Lipofectamine
2000 (Invitrogen). In transactivation assays, 0.25  g of  -galactosidase
plasmid was cotransfected with 1  g reporter plasmid and 2  g of either
 -catenin, or cadherin tail constructs. Cells were plated in duplicates,
lysed after 48 h, and luciferase and  -galactosidase levels were deter-
mined by enzyme assay kits purchased from Promega. Luciferase activity
was normalized to  -galactosidase activity as internal transfection control.
Fold induction of the L1 and Cyclin D1 promoters was calculated using
empty reporter plasmid (PGL2 and PA3luc, respectively). Retroviral infec-
tions were performed with pBabe-puro
r and pBabe-L1 into 293T cells (2  
10
6 cells/10 cm dish), by the calcium phosphate coprecipitation method,
together with the ecotropic packaging vector pSV- -E-MLV providing the
helper function as described previously (Conacci-Sorrell et al., 2002b).
Transfection of the L1 siRNA sequence, 5 -GGAUGGUGUCCACUU-
CAAA-3  and 5 -UUUGAAGUGGACACCAUCC-3  and of control oligo-
nucleotides obtained from QIAGEN was performed with annealed siRNAs
using Oligofectamine (Life Technologies) and the transfected cells were
analyzed after 72 h. LS174T cells stably expressing human L1 were estab-
lished by transfection using Lipofectamine 2000, followed by neo
r selec-
tion. SW707 cells stably expressing human L1 were obtained by trans-
fection with Superfect (Stratagene) and neomycin selection, followed by
enrichment for L1 expression with mAb L1-11A and magnetic beads
(Miltenyi Biotec).
Plasmids
The L1 promoter reporter plasmid containing the transcription initiation site
and 2.9-kb upstream sequences (Kallunki et al., 1997; Meech et al.,
1999), including the four putative LEF/TCF-binding sites, was cloned into
PGL2 (provided by F. Jones, Lois Pope LIFE Center, Miami, FL). Full-length
L1 cDNA (U52112) provided by V. Lemmon (University of Miami, Coral
Gables, FL; Hlavin and Lemmon, 1991) was subcloned into the EcoRI site
of pBabe-puro
r.  NTCF4 was provided by M. van de Wetering and H.
Clevers, as were the TOPFLASH and FOPFLASH synthetic promoter re-
porter plasmids.  LEF was a gift from R. Kemler (Max Planck Institute for
Immunobiology, Freiburg, Germany). The mutant  -catenin S33Y, Cyclin
D1 reporter plasmid, dominant positive LEF-1 construct (Shtutman et al.,
1999) and the plasmid coding for the cytoplasmic domain of E-cadherin
(Cad tail; Sadot et al., 1998) were described previously.
RT-PCR and electrophoretic mobility shift assays
RT-PCR for L1 was performed using the primers: ACGGGCAACAACAG-
CAAC and CGGCTTCCTGTCAATCATG, and for GAPDH: ACCA-
CAGTCCATGCCATCAC and TCCACCACCCTGTTGCTGTA. The primers
for E-cadherin and ADAM10 and PCR conditions were as described previ-
ously (Fogel et al., 2003). For electrophoretic mobility shift assays, dou-
ble-stranded DNA oligonucleotides containing the putative LEF/TCF-bind-
ing sites of the L1 promoter (Fig. 2 C) and 10 adjacent nucleotides
upstream and 10 downstream were used. SW480 cells were harvested,
incubated for 15 min in low-salt buffer, NP-40 was added, nuclei were
pelleted by centrifugation, and nuclear proteins extracted with high-salt
buffer as described previously (Shtutman et al., 1999). For DNA-binding
assays, 6  g of nuclear extract were used. Increasing volumes of poly-
clonal  -catenin antibody were added to the binding reaction to analyze
DNA mobility supershift.
Immunofluorescence
Cells cultured on glass coverslips were permeabilized with 0.5% Triton
X-100 and fixed with 3% PFA in PBS. The coverslips were incubated with
polyclonal antibody against the extracellular domain of L1 provided by
V. Lemmon (Schaefer et al., 1999), or the mAb L1-11A (a subclone de-
rived from hybridoma UJ127.11; Mechtersheimer et al., 2001). The
mAb against  -catenin was purchased from Transduction Laboratories.
The secondary antibodies were Alexa 488–conjugated goat anti–mouse
or anti–rabbit IgG (Molecular Probes) and Cy3-labeled goat anti–mouse,
or anti–rabbit IgG (Jackson ImmunoResearch Laboratories), as described
by Simcha et al. (1998). Images were acquired using the DeltaVision sys-
tem (Applied Precision) equipped with a microscope (model Axiovert
100; Carl Zeiss MicroImaging, Inc.) and Photometrics 300 series scien-
tific-grade cooled CCD camera, reading 12-bit images, and using the
63 /1.4 NA plan-Neofluar objective. Adjustments of brightness, con-
trast, color balance, and final size of images was processed using
Adobe Photoshop 5.5.
Western blotting, cell growth rate and wound healing
Additional antibodies used in Western blotting were mouse anti-tubulin
(Sigma-Aldrich), mouse anti–E-cadherin (Transduction Laboratories), goat
anti-ADAM10 (R&D Systems), mouse anti-MAPK and rabbit antiphosphor-
ylated MAPK (Sigma-Aldrich). The Western blots were developed using
the ECL method (Amersham Biosciences). For cell growth rate, 5   10
3
cells were plated into 24-well dishes and their number determined every
24 h for 6 d in triplicates. Cells were also grown in the presence of anti-THE ROLE OF L1 IN HUMAN COLON CANCER INVASION • GAVERT ET AL. 641
body against L1-CAM, at 1:200 dilution with HCT116 and 1:50 with
SW480 cells. Anti-L1 antibody (boiled for 10 min) was used as control. A
“wound” was introduced into a confluent monolayer of cells with the tip of
a micropipette as described previously (Conacci-Sorrell et al., 2002b), the
culture medium replaced with fresh medium, and 40  g/ml of Mitomycin
C was added to inhibit cell proliferation. After 24 h, the cells were fixed
with ice-cold methanol, stained with Giemsa, and photographed.
FACS analysis, transmigration, and matrigel invasion assays
For FACS analysis, the cells were stained with mAb to L1 and PE-conju-
gated secondary antibodies, or with secondary antibody alone as control
(Mechtersheimer et al., 2001). Stained cells were analyzed with a FAC-
Scan using the Cellquest software (Becton Dickinson). Haptotactic cell mi-
gration assays (toward 10  g/ml fibronectin coated on the backside of
the filter) was performed in Transwell chambers (Costar; Mechtersheimer
et al., 2001). After 16 h, cells that migrated to the backside of the filter
were stained with crystal violet solution and the OD of the eluted dye was
determined at 595 nm in an ELISA reader. Invasion assays were per-
formed with 24-well BioCoat Matrigel Invasion Chambers (Becton Dickin-
son) using 5   10
4 cells in serum-free DME and plated onto either control
or matrigel-coated filters. Conditioned medium from 3T3 cells was placed
in the lower chambers as chemoattractant. After 22 h in culture, cells were
removed from the upper surface of the filter by scraping with a cotton
swab. Cells that invaded through the matrigel and were adherent to the
bottom of the membrane were stained with crystal violet solution. The cell-
associated dye was eluted with 10% acetic acid and its OD at 595 nm
determined. Each experiment was done in quadruplicates and the mean
values  SEM are presented.
Tumorigenicity assays
NIH3T3 cells (10
5 and 2.5   10
5) expressing retrovirally transduced L1,
or the empty (puro
r) vector, or LS174T and LS174T-L1 cells (10
6 cells),
were injected subcutaneously into 6-wk-old CD1 nude male mice. Control
neo
r-LS174T cells were injected on one side, and LS174T-L1 on the other
side of each animal in the presence or absence of matrigel (250  l/ani-
mal), generously provided by H. Kleinman (National Institutes of Health,
Bethesda, MD). Groups of six mice were followed for 2 wk, when the size
of tumors reached  1–2 cm in diameter. After sacrificing the mice, the tu-
mors were excised and weighed. Normal subcutaneous tissue was also
excised, and RNA was prepared from normal and tumor tissue for RT-PCR.
SW707 and SW707-L1 cells (10
7 cells/animal) were injected into the
flanks of 4 scid/nod mice in each group, and tumor volume was deter-
mined at different times after injection by measuring tumor diameter.
Tissue immunohistochemistry
Immunohistochemistry was performed as previously described (Brabletz et
al., 1999). In brief, 3- m serial sections from 25 formalin-fixed, paraffin-
embedded, colorectal adenocarcinomas were deparaffinized, rehydrated,
and pretreated for antigen retrieval by microwave treatment for 20 min in
10  M of citrate buffer, pH 6.0. To detect L1 and ADAM10, the antibod-
ies described above were used. Biotinylated rabbit anti–mouse Ig anti-
serum, or rabbit anti–goat antiserum (both diluted 1:200; DakoCytoma-
tion), served as secondary antibody. To detect L1 and  -catenin (brown
staining), the Envision system was used for ADAM10 (red staining), and
Strept/AB (for  -catenin) was used according to the manufacturer’s proto-
col (DakoCytomation). After rinsing with water, sections were counter-
stained with hemalaun (Merck), dehydrated, and covered with coverslips.
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